Securities code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022023
Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Announcement of resolutions of the 20th meeting of the seventh board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. 1、 Meetings of the board of supervisors
Shanghai Pharmaceuticals Holding Co.Ltd(601607) (hereinafter referred to as “the company”) the 20th meeting of the seventh board of supervisors (hereinafter referred to as “the meeting”) was held in Shanghai Pharmaceuticals Holding Co.Ltd(601607) building, 200 Taicang Road, Shanghai on March 29, 2022. The notice of the meeting was sent to all supervisors of the company by e-mail on March 14, 2022. Three supervisors should be present at this meeting and three actually present, which is in line with the provisions of the company law of the people’s Republic of China and the articles of association on the quorum of the board of supervisors. The meeting was presided over by Xu Yili, chairman of the board of supervisors. 2、 Deliberation at the meeting of the board of supervisors
The following proposals were considered and adopted at this meeting:
1. Work report of the board of supervisors in 2021
The report needs to be submitted to the general meeting of shareholders of the company for deliberation.
Voting results: 3 in favor, 0 against and 0 abstention.
2. Financial final account report of 2021 and financial budget report of 2022
The report needs to be submitted to the general meeting of shareholders of the company for deliberation.
Voting results: 3 in favor, 0 against and 0 abstention.
3. Annual report and summary of 2021
According to relevant regulations, the board of supervisors of the company carefully reviewed the annual report of the company in 2021.
After review, the board of supervisors believes that the preparation and review procedures of the company’s 2021 annual report comply with the provisions of laws, regulations, the articles of association and the company’s internal management system; The content and format of the company’s 2021 annual report comply with the provisions of the China Securities Regulatory Commission and the Shanghai Stock Exchange, and the information contained truly reflects the company’s business management and financial status in 2021; Before putting forward this opinion, the board of supervisors of the company did not find that the personnel involved in the preparation and deliberation of the annual report had violated the confidentiality provisions.
See the website of Shanghai Stock Exchange www.sse.com for details com. cn.。
The proposal still needs to be submitted to the general meeting of shareholders of the company for deliberation.
Voting results: 3 in favor, 0 against and 0 abstention
4. 2021 profit distribution plan
See the company’s Announcement No. 2022030 for details.
In 2021, the company plans to distribute profits based on the total share capital registered on the date of equity distribution. The profit distribution plan is as follows:
The company plans to distribute a cash dividend of 4.20 yuan (including tax) for every 10 shares to all shareholders. As of the date of this announcement, the total share capital including the number of exercised shares of the company’s equity incentive is 2842445936 shares. Based on this calculation, the total amount of cash dividends to be distributed is 11938279312 yuan (including tax), accounting for 23.44% of the consolidated net profit attributable to the shareholders of the listed company in the current year. After distribution, the company’s balance consolidated undistributed profit was 2740477074155 yuan. During the reporting period, no capital reserve will be converted into share capital.
On March 22, 2022, the company received the reply on approving Shanghai Pharmaceuticals Holding Co.Ltd(601607) non-public development of shares issued by China Securities Regulatory Commission, and disclosed the relevant announcement on the same day. Meanwhile, the first batch of options of the company’s 2019 stock option plan are in the vesting period. According to the foregoing, before the equity distribution registration date, the total share capital may change due to non-public offering and equity incentive exercise.
If the total share capital of the company changes between the date of equity distribution and the date of equity registration, the company plans to keep the amount of distribution per share unchanged and adjust the total profit distribution accordingly based on the total share capital on the date of equity distribution. The subsequent company will separately disclose the relevant adjustment announcement according to the actual situation.
The proposal still needs to be submitted to the general meeting of shareholders of the company for deliberation.
Voting results: 3 in favor, 0 against and 0 abstention.
5. Proposal on payment of audit fees and renewal of accounting firm in 2021
See the company’s Announcement No. 2022029 for details.
The proposal still needs to be submitted to the general meeting of shareholders of the company for deliberation.
Voting results: 3 in favor, 0 against and 0 abstention.
6. Proposal on changing accounting policies
See the company’s Announcement No. 2022026 for details.
Voting results: 3 in favor, 0 against and 0 abstention.
It is hereby announced.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) board of supervisors
March 30, 2022
